GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...
GlaxoSmithKline is set to launch its COPD ... had been able to engage with payers much earlier than on previous Ellipta products, which he believes has set it up for a strong launch.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback